Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

3(50.0%)

Phase 3

2(33.3%)

Phase 2

1(16.7%)

6Total

Phase 1(3)

Phase 3(2)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT06254014Phase 3Active Not Recruiting

A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Placebo in T2DM Patients

Role: lead

NCT06257966Phase 3Active Not Recruiting

A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin

Role: lead

NCT06247748Phase 1Completed

Influence of JY09 on Pharmacokinetics of Metformin , Rosuvastatin , and Digoxin and the QT Interval Study in Overweight Chinese Subjects

Role: lead

NCT04874844Phase 2Unknown

JY025 is a First-line Treatment for EGFR Mutated NSCLC Phase II and III Clinical Trials of Efficacy and Safety

Role: lead

NCT04354090Phase 1Completed

Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of JY09

Role: lead

NCT02971722Phase 1Unknown

a Study of JY09 in Chinese Healthy Subjects

Role: lead

All 6 trials loaded